TW200501955A - Method of treatment - Google Patents

Method of treatment

Info

Publication number
TW200501955A
TW200501955A TW093106341A TW93106341A TW200501955A TW 200501955 A TW200501955 A TW 200501955A TW 093106341 A TW093106341 A TW 093106341A TW 93106341 A TW93106341 A TW 93106341A TW 200501955 A TW200501955 A TW 200501955A
Authority
TW
Taiwan
Prior art keywords
treatment
cancers
administering
disease
patient
Prior art date
Application number
TW093106341A
Other languages
English (en)
Chinese (zh)
Inventor
David Bryant Batt
Guido Bold
Sunkyu Kim
Timothy Michael Ramsey
Michael Lloyd Sabio
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TW200501955A publication Critical patent/TW200501955A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Quinoline Compounds (AREA)
TW093106341A 2003-03-11 2004-03-10 Method of treatment TW200501955A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45362403P 2003-03-11 2003-03-11

Publications (1)

Publication Number Publication Date
TW200501955A true TW200501955A (en) 2005-01-16

Family

ID=32990797

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093106341A TW200501955A (en) 2003-03-11 2004-03-10 Method of treatment

Country Status (22)

Country Link
EP (1) EP1603566B1 (enExample)
JP (1) JP2006519807A (enExample)
KR (1) KR20050108383A (enExample)
CN (1) CN1758910A (enExample)
AT (1) ATE421324T1 (enExample)
AU (1) AU2004218914A1 (enExample)
BR (1) BRPI0408257A (enExample)
CA (1) CA2518530A1 (enExample)
DE (1) DE602004019193D1 (enExample)
ES (1) ES2318276T3 (enExample)
HR (1) HRP20050788A2 (enExample)
IS (1) IS8064A (enExample)
MA (1) MA27724A1 (enExample)
MX (1) MXPA05009687A (enExample)
NO (1) NO20054647L (enExample)
PL (1) PL1603566T3 (enExample)
PT (1) PT1603566E (enExample)
RU (1) RU2325159C2 (enExample)
TN (1) TNSN05223A1 (enExample)
TW (1) TW200501955A (enExample)
WO (1) WO2004080464A1 (enExample)
ZA (1) ZA200506571B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2526285A1 (en) 2003-05-15 2004-12-23 Arqule, Inc. Inhibitors of p38 and methods of using the same
PE20050952A1 (es) * 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
WO2006010082A1 (en) 2004-07-08 2006-01-26 Arqule, Inc. 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
CA2584368A1 (en) 2004-10-19 2006-04-27 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
WO2006089781A1 (en) * 2005-02-25 2006-08-31 Novartis Ag Pharmaceutical combination of bcr-abl and raf inhibitors
HRP20110839T1 (hr) * 2005-07-26 2011-12-31 Sanofi Derivati cikloheksaminizokinolona kao inhibitori rho-kinaze
US8318941B2 (en) 2006-07-06 2012-11-27 Bristol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
JP2009077712A (ja) * 2007-09-11 2009-04-16 F Hoffmann La Roche Ag Ｂ−Ｒａｆキナーゼ阻害剤に対する感受性についての診断試験
US8758323B2 (en) 2009-07-30 2014-06-24 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
EP2545187B1 (en) 2010-03-09 2018-09-05 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
CA2816088A1 (en) 2010-10-28 2012-05-03 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN103435430B (zh) * 2013-08-08 2015-02-18 四川大学 一种还原酰胺类化合物的方法
KR102119943B1 (ko) 2018-05-23 2020-06-05 주식회사 포스코 시편배치유닛 및 이를 포함하는 도장밀착성 실험장치
US20210275516A1 (en) * 2018-07-02 2021-09-09 Ecole Polytechnique Federale De Lausanne (Epfl) Lactate enhancing compounds and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
ES2342240T3 (es) * 1998-08-11 2010-07-02 Novartis Ag Derivados de isoquinolina con actividad que inhibe la angiogenia.
AR025752A1 (es) * 1999-09-28 2002-12-11 Bayer Corp Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis
WO2001058899A1 (en) * 2000-02-09 2001-08-16 Novartis Ag Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
US20030078271A1 (en) * 2001-01-31 2003-04-24 Blackburn Thomas P. Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
ATE497603T1 (de) * 2001-03-02 2011-02-15 Gpc Biotech Ag Drei-hybrid-assaysystem
CA2471314A1 (en) * 2001-12-21 2003-07-24 Bayer Pharmaceuticals Corporation Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
US7220775B2 (en) * 2002-08-07 2007-05-22 H. Lundbeck A/S Compound useful for the treatment of neuropathic pain

Also Published As

Publication number Publication date
AU2004218914A1 (en) 2004-09-23
TNSN05223A1 (en) 2007-06-11
RU2005131168A (ru) 2006-05-27
HRP20050788A2 (en) 2006-12-31
JP2006519807A (ja) 2006-08-31
ES2318276T3 (es) 2009-05-01
EP1603566A1 (en) 2005-12-14
BRPI0408257A (pt) 2006-03-07
WO2004080464A1 (en) 2004-09-23
IS8064A (is) 2005-10-10
CA2518530A1 (en) 2004-09-23
EP1603566B1 (en) 2009-01-21
NO20054647D0 (no) 2005-10-10
ZA200506571B (en) 2006-07-26
MXPA05009687A (es) 2005-10-20
RU2325159C2 (ru) 2008-05-27
DE602004019193D1 (de) 2009-03-12
CN1758910A (zh) 2006-04-12
ATE421324T1 (de) 2009-02-15
NO20054647L (no) 2005-12-09
MA27724A1 (fr) 2006-01-02
PL1603566T3 (pl) 2009-07-31
PT1603566E (pt) 2009-04-27
KR20050108383A (ko) 2005-11-16

Similar Documents

Publication Publication Date Title
SG132672A1 (en) 1,4-disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases
TW200621715A (en) Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
MY139942A (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
MXPA05011296A (es) Conjugados de fosfonato inhibidores de la cinasa.
BRPI0411365A (pt) derivados de aminopiridina
TNSN05223A1 (en) Use of isoquinoline derivatives for treating cancer and map kinase related diseases
JO2764B1 (en) Indole derivatives or benzimidazole derivatives to modify the enzyme AKP kinase
PH12013500123A1 (en) Hemiasterlin derivatives and uses thereof
TW200720249A (en) Pyrrolidine compound
NO20026242D0 (no) Syntesemetoder for aplidin og nye antitumorale derivater, metoder for fremstilling og anvendelse av disse
EA200800516A1 (ru) Производные n-фенил-2-пиримидинамина и процесс их получения
PL371127A1 (en) 6-aminomorphinane derivatives, method for the production and use thereof
DE602004023271D1 (de) Metastin derivate und ihre verwendung
WO2005030794A3 (en) Hemiasterlin derivatives and uses thereof
NO20040604L (no) Trisykliske imidazolpyridiner
NO20055033L (no) Cykliske benzimidazoler
IL166057A0 (en) Urea-substituted and urethane-substituted acylureas methods for the production thereof and their useas medicaments
SI1727817T1 (sl) Azabiciklooktan-3-onski derivati in njihova uporaba
BRPI0607285A2 (pt) tratamento de tumores com metástases
DK1485057T3 (da) Derivater af azaspiroforbindelser til behandling af smerter
PT1745010E (pt) Derivados de ciclo-hexil-1,4-diamina substituídos
TW200504068A (en) 6-substituted imidazopyrazines
MXPA04001855A (es) Derivados de sistemas de indan-1-ol c2-sustituidos, metodos para la produccion de los mismos y su uso como medicamentos.
NO20055699L (no) Imidazopyridinintermediater
DE60120398D1 (de) Imidazopyridin-8-one